Moderna Licenses New Vaccine Candidates Against a New Viral Target to Merck

Moderna Licenses New Vaccine Candidates Against a New Viral Target to Merck

January 11, 2016

CAMBRIDGE, Mass., January 11, 2016 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced that Merck, known as MSD outside the United States and Canada, has licensed a vaccine program against an undisclosed viral target, including mRNA 1566 and a set of related novel vaccine candidates, as part of the ongoing collaboration between the companies to discover and develop vaccines and passive immunity treatments against viral diseases using modified messenger RNA (mRNA).

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science

Seres Therapeutics Announces Strategic Collaboration with Nestlé Health Science

January 11, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 11, 2016-- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, announced today that it has entered into an agreement with Nestlé Health Science for the development and commercialization outside of the United States and Canada for its product candidates in development for Clostridium Difficile infection (CDI) and inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease.

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

BIND Therapeutics Presents Complete Data on Clinical Activity of BIND-014 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) at the 2016 Genitourinary Cancers Symposium

January 7, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, today announced the presentation of complete data from its phase 2 clinical trial of BIND-014, a PSMA-targeted ACCURIN containing docetaxel, in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) who either were or were not exposed to anti-androgens (abiraterone acetate and/or enzalutamide).

Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer

Seres Therapeutics Announces Appointment of Wael Hashad as Chief Commercial Officer

January 6, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 6, 2016-- Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President.

Editas Medicine Expands Leadership Team with Key Organizational Appointments

Editas Medicine Expands Leadership Team with Key Organizational Appointments

January 5, 2016

Cambridge, Mass., January 5, 2015 – Editas Medicine, a leading genome editing company, today announced the appointment of Timothy D. Hunt as senior vice president of corporate affairs and Haiyan Jiang, Ph.D., as vice president of preclinical science.

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

Selecta Biosciences Announces Dosing of First Patient in Phase 1b Clinical Trial of SEL-212, Designed to be the First Non-Immunogenic Biologic Treatment for Gout

December 23, 2015

Watertown, Mass. – December 23, 2015 – Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced the dosing of the first patient in the Company's Phase 1b clinical trial to assess the safety, pharmacodynamic profile and efficacy of SEL-212, Selecta's proprietary biologic treatment for refractory and tophaceous gout.

Black Duck Names Jukka Alanen VP of Business Development and Corporate Strategy

Black Duck Names Jukka Alanen VP of Business Development and Corporate Strategy

November 24, 2015

BURLINGTON, MA - November 24, 2015 – Black Duck Software, a global leader in automated solutions for securing and managing open source software, today announced the appointment of Jukka Alanen as its Vice President of Business Development and Corporate Strategy.

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

Celgene and Acceleron Announce New Results from an Investigational Study with Luspatercept in Beta-Thalassemia Presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

December 11, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced preliminary results from two Phase 2 clinical trials of luspatercept in patients with beta-thalassemia were presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition.

Agios Pharmaceuticals, Inc.

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Agios Announces Initiation of Phase 1b Frontline Trial of AG-221 or AG-120 in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

December 18, 2015

CAMBRIDGE, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals Inc., (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1b, multicenter, international, open-label study of AG-221 or AG-120 in combination with induction and consolidation therapy in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are eligible for intensive chemotherapy.

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics Announces Initiation of a Phase 1b Clinical Trial of SER-287 in Mild-to-Moderate Ulcerative Colitis

December 14, 2015

CAMBRIDGE, Mass. (BUSINESS WIRE)--Dec. 14, 2015--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has initiated a Phase 1b clinical trial evaluating SER-287 in mild-to-moderate ulcerative colitis (UC). The program IND has been cleared by the FDA, and clinical investigational sites are now open and actively enrolling patients. SER-287 is the first microbiome therapeutic candidate to reach clinical-stage development in a chronic disease, and the first in an indication outside of infectious disease.